Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Taysha Gene Therapies, Inc. (TSHA : NSDQ)

• Company Description    Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. Number of Employees: 73

• Price / Volume Information    Yesterday's Closing Price: $2.45 Daily Weekly Monthly 20 Day Moving Average: 2,917,308 shares Shares Outstanding: 214.66 (millions) Market Capitalization: $525.92 (millions) Beta: 0.97 52 Week High: $3.31 52 Week Low: $1.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.73% -17.57% 12 Week 96.79% 68.08% Year To Date 41.62% 32.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3000 Pegasus Park Dr. Ste 1430 - DALLAS,TX 75247 USA ph: 214-612-0000 fax: - ir@tayshagtx.com http://www.tayshagtx.com

• General Corporate Information    Officers Sean Nolan - Chief Executive Officer and Director Kamran Alam - Chief Financial Officer Phillip B. Donenberg - Director Sean Stalfort - Director Sukumar Nagendran - Director Peer Information Taysha Gene Therapies, Inc. (BGMR) Taysha Gene Therapies, Inc. (BBIO) Taysha Gene Therapies, Inc. (IPAH) Taysha Gene Therapies, Inc. (BRL) Taysha Gene Therapies, Inc. (BHC) Taysha Gene Therapies, Inc. (AKRXQ) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-GENERIC DRG Sector: Medical CUSIP: 877619106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 214.66 Most Recent Split Date: (:1) Beta: 0.97 Market Capitalization: $525.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 9.12 Price/Cash Flow: - Price / Sales: 72.80 EPS Growth vs. Year Ago Period: 20.00% vs. Previous Quarter: -14.29% Sales Growth vs. Year Ago Period: -32.51% vs. Previous Quarter: 13.85% ROE 06/30/25 - - 03/31/25 - -104.93 12/31/24 - -108.46 ROA 06/30/25 - - 03/31/25 - -50.09 12/31/24 - -50.49 Current Ratio 06/30/25 - - 03/31/25 - 5.35 12/31/24 - 5.42 Quick Ratio 06/30/25 - - 03/31/25 - 5.35 12/31/24 - 5.42 Operating Margin 06/30/25 - - 03/31/25 - -1,177.51 12/31/24 - -1,051.18 Net Margin 06/30/25 - - 03/31/25 - -1,201.08 12/31/24 - -1,071.62 Pre-Tax Margin 06/30/25 - - 03/31/25 - -1,201.08 12/31/24 - -1,071.62 Book Value 06/30/25 - - 03/31/25 - 0.27 12/31/24 - 0.35 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.77 12/31/24 - 0.61 Debt-to-Capital 06/30/25 - - 03/31/25 - 43.54 12/31/24 - 38.06

Powered by Zacks Investment Research ©